IDEAYA Biosciences to Participate in Upcoming July 2025 Investor Relations Event
IDEAYA Biosciences (NASDAQ: IDYA), a precision medicine oncology company, will participate in the 2025 BTIG Virtual Biotechnology Conference on July 29th, 2025. The company's President and CEO, Yujiro S. Hata, will engage in a fireside chat at 4:40 PM ET, hosted by BTIG's Director of Biotechnology Research Analysis, Justin Zelin.
The event will be accessible via live audio webcast through the company's investor relations website, with replay available for 30 days after the event.
IDEAYA Biosciences (NASDAQ: IDYA), un'azienda di oncologia di medicina di precisione, parteciperà alla Conferenza Virtuale di Biotecnologia BTIG 2025 il 29 luglio 2025. Il Presidente e CEO dell'azienda, Yujiro S. Hata, prenderà parte a una conversazione informale alle 16:40 ET, condotta da Justin Zelin, Direttore dell'Analisi della Ricerca Biotecnologica di BTIG.
L'evento sarà accessibile tramite webcast audio in diretta sul sito web delle relazioni con gli investitori dell'azienda, con la possibilità di rivederlo per 30 giorni dopo la trasmissione.
IDEAYA Biosciences (NASDAQ: IDYA), una compañía de oncología de medicina de precisión, participará en la Conferencia Virtual de Biotecnología BTIG 2025 el 29 de julio de 2025. El presidente y CEO de la compañía, Yujiro S. Hata, participará en una charla informal a las 4:40 PM ET, presentada por Justin Zelin, Director de Análisis de Investigación en Biotecnología de BTIG.
El evento será accesible mediante una transmisión de audio en vivo a través del sitio web de relaciones con inversionistas de la compañía, con repetición disponible durante 30 días después del evento.
IDEAYA 바이오사이언스 (NASDAQ: IDYA)는 정밀 의학 종양학 회사로서 2025년 7월 29일에 열리는 2025 BTIG 가상 생명공학 컨퍼런스에 참여합니다. 회사의 사장 겸 CEO인 유지로 S. 하타는 BTIG 생명공학 연구 분석 담당 이사 저스틴 젤린이 진행하는 동부 표준시 오후 4시 40분의 대화에 참여할 예정입니다.
이 행사는 회사의 투자자 관계 웹사이트를 통해 실시간 오디오 웹캐스트로 제공되며, 행사가 끝난 후 30일 동안 다시보기가 가능합니다.
IDEAYA Biosciences (NASDAQ : IDYA), une société d'oncologie en médecine de précision, participera à la Conférence virtuelle de biotechnologie BTIG 2025 le 29 juillet 2025. Le président et CEO de la société, Yujiro S. Hata, participera à une discussion informelle à 16h40 ET, animée par Justin Zelin, directeur de l'analyse de la recherche en biotechnologie chez BTIG.
L'événement sera accessible via un webcast audio en direct sur le site des relations investisseurs de la société, avec une rediffusion disponible pendant 30 jours après l'événement.
IDEAYA Biosciences (NASDAQ: IDYA), ein Unternehmen für Präzisionsmedizin in der Onkologie, wird am BTIG Virtual Biotechnology Conference 2025 am 29. Juli 2025 teilnehmen. Der Präsident und CEO des Unternehmens, Yujiro S. Hata, wird um 16:40 Uhr ET an einem Gespräch am Kamin teilnehmen, moderiert von Justin Zelin, Direktor der Biotechnologieforschungsanalyse bei BTIG.
Die Veranstaltung ist über einen Live-Audio-Webcast auf der Investor-Relations-Website des Unternehmens zugänglich, mit einer Wiedergabeoption für 30 Tage nach der Veranstaltung.
- None.
- None.
2025 BTIG Virtual Biotechnology Conference
Tuesday, July 29th, 2025 at 4:40 PM ET
- Fireside chat with Yujiro S. Hata, President and Chief Executive Officer, hosted by Justin Zelin, Director, Biotechnology Research Analyst
A live audio webcast of the conference event, as permitted by the conference host, will be available at the "Investors/Events" section of the IDEAYA website at https://ir.ideayabio.com/events and/or through the conference host. A replay of available webcasts will be accessible for 30 days following the live event.
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies to address unmet medical needs in cancer. The company integrates small molecule drug discovery, structural biology and bioinformatics with extensive capabilities in identifying and validating translational biomarkers to develop potentially first-in-class targeted therapies for selected patient populations. IDEAYA has built a robust pipeline of targeted therapies focused on synthetic lethality and antibody-drug conjugates, or ADCs, including bispecifics, with the goal of improving clinical outcomes for patients with cancer.
Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to participation in and/or presentation at certain investor relations events. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's current and future filings with the
Investor and Media Contact
IDEAYA Biosciences
Joshua Bleharski, Ph.D.
Chief Financial Officer
investor@ideayabio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-to-participate-in-upcoming-july-2025-investor-relations-event-302509000.html
SOURCE IDEAYA Biosciences, Inc.
FAQ
When is IDEAYA Biosciences (IDYA) presenting at the BTIG Virtual Biotechnology Conference 2025?
Who will be presenting at the IDEAYA Biosciences (IDYA) BTIG conference?
How can investors access IDEAYA Biosciences' (IDYA) BTIG conference presentation?
What type of company is IDEAYA Biosciences (IDYA)?
